Market Size and Overview:

The projected value for the Global Market of Deep Brain Stimulation (DBS) Devices catering to Huntington Disease in 2023 was forecasted to reach $2.22 billion, with an anticipated increase to $4.68 billion by the year 2030. A Compound Annual Growth Rate (CAGR) of 11.2% is expected for the market expansion between 2024 and 2030.

Market Overview

The landscape of Huntington's disease (HD) therapy witnesses the emergence of deep brain stimulation (DBS), a method addressing the neurodegenerative effects on mobility, cognition, and behavior. Despite the absence of FDA-approved DBS devices specifically designed for HD, the overall DBS devices market is experiencing rapid growth, fueled by the creation of new devices and expanding applications by various companies.

Compared to prevalent neurological conditions like Parkinson's disease, dominating DBS surgeries, the market for DBS devices dedicated to HD remains relatively small. However, as ongoing clinical trials affirm the safety and efficacy of DBS for HD, projections indicate a significant expansion in this market.

DBS Devices for Huntington Disease Market Drivers

Increasing Prevalence of HD Driving Market Growth:

The rarity of Huntington's disease, affecting approximately one in every 10,000 individuals globally, contrasts with other neurological conditions. Advances in genetic testing have facilitated easier HD diagnosis and identification of individuals at risk. The anticipated rise in the HD-affected population is expected to drive demand for innovative therapies, such as DBS.

Growing Awareness of DBS as a Treatment Option:

Enhanced understanding of the potential benefits of DBS for HD, supported by increasing evidence of safety and effectiveness in clinical trials, is driving awareness among both patients and medical professionals. Recognized as a relatively non-invasive procedure with the potential to improve the quality of life and motor function in HD patients, the demand for DBS devices is likely to surge as its therapeutic potential becomes more widely known.

DBS Devices for Huntington Disease Market Challenges

Lack of FDA Approval Hindering Market Growth:

The absence of specific FDA approval for DBS devices tailored for HD treatment poses a challenge. While certain DBS devices are used off-label for HD, their approval is for other neurological conditions like Parkinson's disease. This regulatory gap may lead healthcare professionals to hesitate in recommending off-label therapies, potentially impeding market growth by creating regulatory and reimbursement obstacles.

Limited Awareness and Understanding of HD:

Huntington's disease being a rare and often misunderstood disorder hampers awareness among healthcare providers and patients. This limited awareness extends to DBS as a treatment option for HD, restricting market growth. Additionally, misconceptions and stigma surrounding HD may further impede the acceptance of DBS devices for treating the disease. Healthcare providers' reluctance to recommend DBS may arise from concerns about the invasiveness of the procedure and potential risks and side effects.

Impact of COVID-19 on DBS Devices for Huntington Disease Market

The sales of DBS devices for Huntington's disease have faced significant repercussions due to the COVID-19 pandemic. The disruption caused by the pandemic, particularly in the continuity of medical care for HD patients, has led to delays in diagnosis and treatment. Despite these challenges, the industry must persevere to advance the development and provision of DBS devices, ensuring that HD patients in need of medical treatment continue to receive timely and effective interventions.

DBS Devices for Huntington Disease Market Segmentation – By Type

In the categorization of DBS Devices for Huntington Disease, there are two primary types:

• Single- Channel DBS Devices
• Multi- Channel DBS Devices

Single-channel DBS devices hold a substantial market share. These devices involve the implantation of a single electrode in a specific location within the brain. The electrode is connected to an implanted pulse generator (IPG), which facilitates electrical stimulation of the brain. While limited to a single electrode, these devices remain effective in their focused application.

Multi-channel DBS devices, in contrast, feature multiple electrodes. These electrodes can be employed to stimulate various areas of the brain simultaneously. The utilization of multiple electrodes enhances adaptability and precision, especially when targeting specific and intricate brain regions. This capability proves valuable in addressing complex Huntington Disease symptoms.

DBS Devices for Huntington Disease Market Segmentation – By End User

The end-user segmentation of DBS devices for Huntington Disease consists of:

• Hospitals and Clinics
• Home Care

Primary end-users of DBS devices for HD are hospitals and clinics. Equipped with specialized neurology and neurosurgery departments, these facilities are adept at performing the surgical implantation of the device and providing comprehensive post-operative care. Due to the intricacy of the procedure, the use of DBS devices is predominantly limited to highly specialized medical institutions.

While hospitals and clinics remain pivotal, there is an emerging trend in using DBS devices for HD in home care settings. This may involve the assistance of a caregiver or a trained medical professional. Home care settings offer convenience for patients who face challenges in traveling to medical facilities or require ongoing monitoring and support.

DBS Devices for Huntington Disease Market Segmentation – By Application

The application-based segmentation includes:

• Motor Symptoms
• Psychiatric Symptoms
• Cognitive Symptoms

Predominantly, DBS devices are applied to address motor symptoms such as chorea, dystonia, and rigidity associated with Huntington Disease. These devices contribute to enhancing motor control and mitigating unintentional movements, significantly impacting the quality of life for HD patients.

DBS devices also play a role in managing psychiatric symptoms like sadness, anxiety, and irritability. While the treatment of mental symptoms is a developing field, the interest in DBS capacity in this regard is on the rise.

Addressing cognitive symptoms, including memory loss and poor executive function, is an area where DBS devices show potential. However, further research is essential to ascertain the efficacy of DBS in controlling cognitive issues as it is still in its early phases of utilization.

DBS Devices for Huntington Disease Market Segmentation – By Region

Geographically, the segmentation includes:

• North America
• Europe
• Asia-Pacific
• Rest of the World

North America, particularly the United States, is expected to maintain its position as the largest market for DBS devices for HD. The region's high incidence of HD and advanced healthcare infrastructure contribute to this dominance.

Europe, with its significant prevalence of HD, is anticipated to be the second-largest market. Key markets such as the United Kingdom, France, and Germany are projected to drive market expansion.

Asia-Pacific is expected to witness the fastest growth in this industry, attributed to the increasing prevalence of HD and a growing understanding of the benefits of DBS devices. China, India, and Japan are forecasted to be the major contributors to market expansion.

The rest of the world market, encompassing Africa, the Middle East, and Latin America, is projected to experience slower growth. Limited awareness of DBS device benefits and a scarcity of advanced healthcare infrastructure contribute to this trend.

Key Players:

Some prominent players in the DBS Devices for Huntington Disease Market include:

• Medtronic
• Boston Scientific Corporation
• Abbott Laboratories
• Beijing PINS Medical Co., Ltd.
• SceneRay Corporation
• Functional Neuromodulation Ltd.
• NeuroPace, Inc.
• AlevaNeurotherapeutics SA
• Sapiens Steering Brain Stimulation B.V.
• Neuros Medical, Inc.